FACTOR VII
Background and Date of Approval
Factor VII received its initial approval from the United States Food and Drug Administration (FDA) on March 25, 1999.
Uses
Factor VII is primarily used to treat bleeding disorders. Its key applications include managing bleeding episodes in hemophilia patients with inhibitors, addressing congenital Factor VII deficiency, controlling bleeding during surgery and trauma, managing acquired Factor VII deficiency associated with certain medical conditions, and occasionally, as part of treatment strategies for intracranial hemorrhage.
How is it administered?
Factor VII concentrates are typically administered intravenously (IV) to individuals with bleeding disorders. A healthcare provider should determine the specific dosing and administration details based on the patient's condition and needs.
Side Effects
Factor VII can have several potential side effects, ranging from common to serious. Common side effects may include fever, headache, nausea, vomiting, and injection site reactions. However, more serious side effects can occur, including thromboembolic events (such as deep vein thrombosis and pulmonary embolism), hypersensitivity reactions (anaphylaxis), arterial thrombosis, disseminated intravascular coagulation (DIC), and bleeding.
Warnings
Factor VII is associated with an increased risk of thromboembolic events, including deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis. Severe allergic reactions (anaphylaxis) to this medication have been reported. When using this for intracranial hemorrhage, there is a concern of exacerbating thrombosis within the brain's blood vessels.
Precautions
Patients with a history of thromboembolic events, underlying cardiovascular conditions, or other risk factors for clot formation should be carefully assessed before using Factor VII. Patients should be monitored for signs of hypersensitivity during and after administration. Immediate treatment should be available in case of an allergic reaction. Neurological monitoring and consultation with a neurologist or neurosurgeon may be done.
Word of Advice
Monitor for allergic reactions and risk of thrombotic events following Factor VII administration. Dosage and effects on coagulation require close surveillance. Patients with hepatic impairment, renal dysfunction, cardiac conditions, or prior thromboembolism warrant particular caution. Paediatric and geriatric patients require additional consideration. Correct administration technique, appropriate storage, and patient education on medication use are essential. Contingency measures should address potential adverse events. Factor VIII inhibitor development and genetic polymorphisms in individual patients must be evaluated. Individualised management through ongoing dialogue between healthcare provider and patient optimises clinical outcomes.
References
Novo Nordisk A/S, Electronic medicines compendium (EMC), [Revised on 13 Jun 2023] [ Accessed on 2nd September 2023], https://www.medicines.org.uk/emc/files/pil.7927.pdf LFB S.A. Puteaux, US Food and Drug Administration, [Revised on Dec 2022] [ Accessed on 2nd September 2023], https://www.fda.gov/media/136610/download Katherine F Croom, Paul L McCormack; Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders; BioDrugs; Published on 2008; Accessed on 02/09/2023; https://pubmed.ncbi.nlm.nih.gov/18345709/
Frequently Asked Questions
What should I do in an emergency or if I experience adverse effects while using Factor VII?
In emergencies or if you experience severe adverse effects, seek immediate medical attention. Have an emergency plan in place for unexpected issues while using this medication.
Can Factor VII be self-administered at home?
Some patients with bleeding disorders may be trained to self-administer Factor VII concentrates at home. However, this depends on individual circumstances and should be supervised by healthcare professionals.
Are there any dietary restrictions while using Factor VII?
There are typically no specific dietary restrictions associated with Factor VII concentrates. However, maintaining a balanced diet and staying well-hydrated can support overall health.
Is genetic testing necessary before using Factor VII?
In some cases, genetic testing may be considered to identify genetic variations that could impact the patient's response to treatment. However, it is only sometimes required for some patients.
Is Factor VII therapy lifelong for individuals with bleeding disorders?
The duration of Factor VII concentrate therapy varies depending on the underlying bleeding disorder and the patient's response to treatment. Some individuals may require lifelong treatment, while others may use it as needed.